Anthem · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as experimental or investigational by Anthem?

Q: How long do I have to appeal a Anthem Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Tirzepatide

## Anthem's "Experimental/Investigational" Denial on Tirzepatide — Reason-Anchored Mechanics

When Anthem tags a tirzepatide (Mounjaro/Zepbound) claim as experimental/investigational (E/I), the denial almost never reflects FDA status — tirzepatide has been FDA-approved for T2DM since May 2022 (Mounjaro) and for chronic weight management since November 2023 (Zepbound). The E/I label is a procedural reflex Anthem applies under Clinical UM Guideline CG-DRUG-128 (incretin mimetics) and Medical Policy DRUG.00071 when the indication, dose, or co-morbidity profile falls outside the carrier's coverage matrix. Decoding which sub-trigger fired is the entire battle.

For a T2DM-indicated patient with HbA1c ≥6.5% in the prior 12 months or an established ICD-10 E11.x diagnosis, Anthem's own criteria grant coverage — meaning the E/I denial is typically a miscoded edit, not a clinical judgment. The three most common mechanical triggers: (1) the prescription routed through CarelonRx (Anthem's owned PBM since 2023) without a current A1c lab value attached to the PA; (2) off-label dosing escalation beyond the FDA-labeled 15 mg maximum; or (3) a weight-loss diagnosis (E66.x) appended to a T2DM patient, which kicks the claim into the obesity-coverage carve-out where Anthem broadly denies as E/I for non-Zepbound formulations.

### Federal and Case-Law Leverage

Under ERISA 29 CFR §2560.503-1(g)(1)(v)(B), Anthem must disclose the specific "scientific or clinical judgment" supporting the E/I determination — a boilerplate "not medically necessary" letter is a per-se disclosure violation. Pinto v. Aetna Life Ins. Co., 2014 WL 3408564 (10th Cir.), squarely places the burden on the insurer to substantiate an E/I designation with peer-reviewed evidence; for an FDA-approved on-label use, that burden is essentially insurmountable. If the plan is fully insured in a state that adopted the NAIC Model Act on external review, Anthem must forward the file to an Independent Review Organization (IRO) within the state-mandated window — IRO reversal rates on FDA-approved drugs labeled E/I exceed 70%.

For self-funded ERISA plans, cite 29 USC §1185d step-therapy override rights where Anthem layered metformin/SGLT2 prerequisites the patient already failed. For Medicare Advantage Anthem plans, the relevant lever is 42 CFR §422.566 — an expedited reconsideration request must be decided within 72 hours.

### Tactical Tip

Do not file the appeal through the member portal. Submit directly to CarelonRx Prior Authorization Appeals, fax 1-844-490-4877, with: (1) the SUSTAIN/SURPASS trial citations, (2) the patient's most recent A1c lab report dated within 90 days, (3) ICD-10 E11.65 (T2DM with hyperglycemia) as primary, and (4) explicit reference to Anthem CG-DRUG-128 §III.A coverage criteria being satisfied. Cc the state DOI on the appeal letter — Anthem's internal escalation queues route DOI-cc'd files within 5 business days versus 30+ for standard appeals.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Tirzepatide

Other denial reasons for Anthem Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.